Investors might want to bet on Aurinia Pharmaceuticals (AUPH), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...

EDMONTON, Alberta (AP) — EDMONTON, Alberta (AP) — Aurinia Pharmaceuticals Inc. (AUPH) on Thursday reported second-quarter earnings of $21.5 million. On a per-share basis, the Edmonton, Alberta-based ...

Aurinia reported $0.16 EPS in Q1 vs. $(0.07) last year, beating estimates of $0.10. LUPKYNIS sales rose 25% year over year to $60 million in Q1. Live on Wednesday June 18: 3 Summer "Power Patterns" ...

Aurinia Pharmaceuticals (AUPH) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring. Aurinia on Thursday unveiled a strategic overhaul that ...

Peter Greenleaf, President and Chief Executive Officer of Aurinia, remains a Director Kevin Tang, President of Tang Capital Management, LLC, appointed as a Director The Board has accepted the ...

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announced today that the first participant has been dosed in a Phase 1a single ...